Talimogene laherparepvec: all 41 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1RecruitingNCT07102394Phase 1
• Neoadjuvant Combination Immunotherapy for Stage III MelanomaRecruitingNCT03842943Phase 2
• TVEC and Preop Radiation for Sarcoma (8 ml Dose)Active, not recruitingNCT04599062Phase 1/2Results posted
• Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the SkinTerminatedNCT04163952Phase 1Results posted
• Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).CompletedNCT04068181Phase 2Results posted
• Study of T-VEC in Locally Advanced Cutaneous AngiosarcomaTerminatedNCT03921073Phase 2Results posted
• Talimogene Laherparepvec for the Treatment of Peritoneal Surface MalignanciesCompletedNCT03663712Phase 1Results posted
• A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural EffusionTerminatedNCT03597009Phase 1/2Results posted
• Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal CancerTerminatedNCT03300544Phase 1Results posted
• Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver MetastasesCompletedNCT03256344Phase 1Results posted
• A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced SarcomaActive, not recruitingNCT03069378Phase 2Results posted
• Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant MelanomaCompletedNCT03064763Phase 1Results posted
• Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV MelanomaActive, not recruitingNCT02965716Phase 2Results posted
• Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast CancerCompletedNCT02779855Phase 1/2Results posted
• Study of Talimogene Laherparepvec In Children With Advanced Non CNS TumorsCompletedNCT02756845Phase 1Results posted
• Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by SurgeryTerminatedNCT02658812Phase 2Results posted
• Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)CompletedNCT02626000Phase 1Results posted
• An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)CompletedNCT02574260Phase 2Results posted
• TVEC and Preop Radiation for Sarcoma (4 ml Dose)CompletedNCT02453191Phase 1/2Results posted
• Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected MelanomaCompletedNCT02366195Phase 2Results posted
• Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected MelanomaTerminatedNCT02263508Phase 3Results posted
• Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for MelanomaCompletedNCT02211131Phase 2Results posted
• Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene LaherparepvecCompletedNCT02014441Phase 2Results posted
• Ipilimumab With or Without Talimogene Laherparepvec in Unresected MelanomaCompletedNCT01740297Phase 1/2Results posted
• An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in MelanomaCompletedNCT01368276Phase 3Results posted
• Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck CancerTerminatedNCT01161498Phase 3Results posted
• Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in MelanomaCompletedNCT00769704Phase 3Results posted
• Talimogene Laherparepvec in Patients With Unresectable Pancreatic CancerCompletedNCT00402025Phase 1Results posted
• A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant MelanomaCompletedNCT00289016Phase 2Results posted
• Neoadjuvant Intralesional Injection of Talimogene LaherparepvecActive, not recruitingNCT06660810Phase 2
• Neoadjuvant T-VEC in High Risk Early MelanomaSuspendedNCT04427306Phase 2
• Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable DiseaseCompletedNCT04330430Phase 2
• Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deletedTerminatedNCT04185311Phase 1
• Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi SarcomaStatus unknownNCT04065152Phase 2
• Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant MelanomaWithdrawnNCT03972046Phase 2
• Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast CancerCompletedNCT03802604Early Phase 1
• TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion)CompletedNCT03555032Phase 1/2
• Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell CarcinomaWithdrawnNCT03430687Phase 1
• Study of Talimogene Laherparepvec (T-VEC) in Pancreatic CancerCompletedNCT03086642Phase 1
• Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersActive, not recruitingNCT02978625Phase 2
• Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by SurgeryActive, not recruitingNCT02923778Phase 2

← Talimogene laherparepvec overview